A Phase 2/3 interventional study of Olokizumab 64 mg and Placebo in COVID-19, sponsored by R-Pharm. Withdrawn. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-11-08.
Sponsored by R-Pharm · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.
Maximum expected study duration for each patient is 62 days, including 2 days of screening, 1 day of study drug administration, and 59 days of follow-up.
The study will include following periods:
Treatment period lasting from the beginning of Day 1 visit to 23:59 of the Day 1.
Eligible patients will be randomized to one of two treatment groups to receive a single subcutaneous injection - OKZ 64 mg or placebo in addition to standard COVID-19 therapy according to institutional guidelines;
Up to 376 randomized patients (full sample size) will be included in the study according to preliminary estimation.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
\<0,5 х 10\^9/L white blood cell count \< 2 х 10\^9/L, count \< 50 х 10\^9/L, (АLT) and/or Aspartate aminotransferase (AST) ≥3,0 х (ULN)
other immunosuppressive drugs (excluding methotrexate in dose up to 25 mg/week), including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
Drug: Olokizumab 64 mg
Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy
Drug: Placebo
solution for subcutaneous administration 160 mg/mL
Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category
Difference between OKZ and placebo groups in the percentage of subjects with an improvement of at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category. The points of the scale are: 1. Not hospitalized; 2.Hospitalized, not requiring supplemental oxygen; 3.Hospitalized, supplemental oxygen, spontaneous breathing;4. Hospitalized, mechanical ventilation (invasive/non-invasive) or extracorporeal membrane oxygenation (ECMO); 5. Death
Time frame: at Day 29
Subjects' clinical status distribution based on 5-point clinical status scale during the study
Subjects' clinical status distribution based on 5-point clinical status scale during the study
Time frame: from Day 2 tо Day 15, Day 29, Day 60
28-day case fatality rates
28-day case fatality rates
Time frame: from Day 1 to Day 29
Case fatality rates during the intensive care unit (ICU) stay, at Days 7, 15, and 60
Case fatality rates during the intensive care unit (ICU) stay at Days 7, 15, and 60
Time frame: from Day 1 to Day 60
Duration of oxygen support
Duration of oxygen support (if applicable)
Time frame: From Day 1 to Day 60
The time period until SpO2 ≥ 94% at ambient air during 2 consequence days is reached
The time period until SpO2 ≥ 94% at ambient air during 2 consequence days is reached
Time frame: from Day 2 to Day 60
Changes of oxygenation index PaO2/FiO2 from baseline
Changes of oxygenation index PaO2/FiO2 from baseline (if applicable)
Time frame: from Day 2 to Day 60
Duration of oxygen support (if applicable)
Duration of oxygen support (if applicable), in days
Time frame: from Day 1 to Day 60
Duration of mechanical ventilation and/or ECMO (if applicable)
Duration of mechanical ventilation and/or ECMO (if applicable), in days
Time frame: from Day 1 to Day 60
Duration of ICU stay (if applicable)
Duration of ICU stay (if applicable)
Time frame: from Day 1 to Day 60
Changes from baseline of COVID-19 cytokine storm surrogate marker: white blood count
Changes from baseline of COVID-19 cytokine storm surrogate marker: white blood count
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker: lymphocyte count
Changes from baseline of COVID-19 cytokine storm surrogate marker: lymphocyte counts
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker: neutrophils count
Changes from baseline of COVID-19 cytokine storm surrogate marker: neutrophils count
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker: C-reactive protein (CRP)
Changes from baseline of COVID-19 cytokine storm surrogate marker: C-reactive protein (CRP)
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker: ferritin
Changes from baseline of COVID-19 cytokine storm surrogate marker: ferritin
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker:D-dimer
Changes from baseline of COVID-19 cytokine storm surrogate marker:D-dimer
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker:platelets
Changes from baseline of COVID-19 cytokine storm surrogate marker:platelets
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
Changes from baseline of COVID-19 cytokine storm surrogate marker: triglycerides
Changes from baseline of COVID-19 cytokine storm surrogate marker: triglycerides
Time frame: from Day 2 and until the end of hospitalization, Day 29 as a maximum
The time period until National Early Warning Score 2 (NEWS2) ≤ 2 during 2 consequent days is reached
The time period until National Early Warning Score 2 (NEWS2) ≤ 2 during 2 consequent days is reached
Time frame: from Day 1 and until the end of hospitalization, Day 29 as a maximum
The time period until National Early Warning Score 2 (NEWS2) ≤ 4 during 2 consequent days is reached
The time period until National Early Warning Score 2 (NEWS2) ≤ 4 during 2 consequent days is reached
Time frame: from Day 1 and until the end of hospitalization, Day 29 as a maximum
No study locations are listed for this record.
Start is estimated for Jun 2020; primary completion for Nov 2020, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olokizumab